Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review

被引：0

作者：

Samoilova, Iuliia G. ^{[1
]}

Vaizova, Olga E. ^{[1
]}

Stankova, Anastasia E. ^{[1
]}

Matveeva, Mariia, V ^{[1
]}

Podchinenova, Daria, V ^{[1
,4
]}

Kudlay, Dmitry A. ^{[2
,3
]}

Borozinets, Anastasiia A. ^{[2
]}

Filippova, Tatyana A. ^{[1
]}

Grishkevich, Ivan R. ^{[1
]}

Partala, Anastasia, V ^{[1
]}

Gerasimova, Diana A. ^{[1
]}

机构：

[1] Siberia State Med Univ, Tomsk, Russia

[2] Sechenov First Moscow State Med Univ, Sechenov Moscow State Med Univ 1, Moscow, Russia

[3] Lomonosov Moscow State Univ, Moscow, Russia

[4] Inst Immunol, Natl Res Ctr, Moscow, Russia

来源：

TERAPEVTICHESKII ARKHIV | 2024年 / 96卷 / 01期

关键词：

polymorphism; dipeptidyl peptidase-4 inhibitors; type 2 diabetes mellitus; GLP1R; DPP-4; KCNQ1; GLYCEMIC RESPONSE; EPIDEMIOLOGY; GENE;

D O I：

10.26442/00403660.2024.01.202553

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The review addresses publications on genetic polymorphisms that potentially impact the effectiveness of therapy with hypoglycemic drugs of the dipeptidyl peptidase -4 inhibitor group. The literature was searched in the PubMed database from 2017 to 2023. Polymorphisms of several genes (GLP1R, TCF7L2, DPP -4, KCNQ1, KCNJ11, PNPLA3, PRKD1) are associated with the pharmacokinetic values and efficacy of dipeptidyl peptidase -4 inhibitors, which may be promising for personalizing the treatment of patients with type 2 diabetes mellitus.

引用

页码：63 / 67

页数：5

共 50 条

[1] Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Neumiller, Joshua J.
Wood, Lindy
Campbell, R. Keith
PHARMACOTHERAPY, 2010, 30 (05): : 463 - 484
[2] Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F.
DIABETES OBESITY & METABOLISM, 2011, 13 (01): : 7 - 18
[3] SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
Lizan, L.
Aceituno, S.
Franch, J.
Perez, A.
Granell, M.
Fuster, E.
VALUE IN HEALTH, 2014, 17 (07) : A348 - A348
[4] The Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus: Cardiovascular Safety
Green, Jennifer B.
POSTGRADUATE MEDICINE, 2012, 124 (04) : 54 - 61
[5] Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review
Ruan, Zhen
Zou, Huimin
Lei, Qing
Ung, Carolina Oi Lam
Shi, Honghao
Hu, Hao
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 555 - 574
[6] Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
Jang, Yun-Mi
Kim, Dong-Lim
DIABETES & METABOLISM JOURNAL, 2011, 35 (02) : 117 - 118
[7] Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
不详
JOURNAL OF DIABETES, 2009, 1 (01) : 6 - 7
[8] Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus
Li, Ning
Wang, Li-Jun
Jiang, Bo
Li, Xiang-qian
Guo, Chuan-long
Guo, Shu-ju
Shi, Da-Yong
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 151 : 145 - 157
[9] Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
Richter, B.
Bandeira-Echtler, E.
Bergerhoff, K.
Lerch, C. L.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (02):
[10] Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
Dave, Darshan J.
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2011, 2 (04) : 230 - 235

← 1 2 3 4 5 →